Pharmaceutical compositions for the treatment of female sexual disorders

• US 20060025420A1
• Filed: 07/22/2005
• Published: 02/02/2006
• Est. Priority Date: 07/30/2004
• Status: Abandoned Application

• Current Assignee: Boehringer Ingelheim Pharmaceuticals Incorporated (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG), Boehringer Ingelheim Pharmaceuticals Incorporated (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Pyke, Robert, Brauns, Ulrich, Froemder, Arne
• Application Number:
  US11/187,422
• Publication Number:
  US 20060025420A1
• Time in Patent Office: Days
• US Class Current: 514/252.160
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/02 for disorders of the vagina
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to a method for the treatment of female sexual disorders comprising administration of a therapeutically effective amount of a compound of general formula 1 wherein the groups R, L and X may have the meanings specified in the description and claims.

Claims

1. ) A method for the treatment of female sexual disorders comprising administration of therapeutically effective amount of a compound of formula 1

wherein

R¹ is a group selected from among halogen, —

O—

C₁-C₄-alkyl, and —

C(halogen)₃;

L is a linker, selected from the bridging groups —

C₁-C₆-alkylene, —

C₁-C₄-alkylene-O—

, —

C₁-C₄-alkylene-O—

CO—

, —

C₁-C₄-alkylene-N H—

, —

C₁-C₄-alkylene-NH—

CO—

, —

C₂-C₆-alkenylene, —

C₂-C₄-alkenylene-O—

, —

C₂-C₄-alkenylene-O—

CO—

, —

C₂-C₄-alkenylene-NH—

, —

C₂-C₄-alkenylene-NH—

CO—

, —

C₂-C₆-alkynylene, —

C₂-C₄-alkynylene-O—

, —

C₂-C₄-alkynylene-O—

CO—

, —

C₂-C₄-alkynylene-N H—

, and

—

C₂-C₄-alkynylene-NH—

CO—

, which may optionally be substituted by one or more, preferably one group selected from among —

C₁-C₄-alkyl, —

OH, halogen, ═

O, —

C(halogen)₃ and —

O—

C₁-C₄-alkyl;

R² is —

NH₂, —

NHC₁-C₄-alkyl, —

N(C₁-C₄-alkyl)₂, or a group selected from among —

C₁-C₆-alkyl and —

C₃-C₆-cycloalkyl which may optionally be substituted by one or more, preferably one group selected from among —

C₁-C₄-alkyl, —

OH, halogen, ═

O, —

C(halogen)₃, —

O—

C₁-C₄-alkyl, —

O—

C₆-C₁₀-aryl, —

NH₂, —

NHC₁-C₄-alkyl, —

N(C₁-C₄-alkyl)₂, —

C₂-C₄-alkenyl and —

C₂-C₄-alkynyl, or

R² is —

C₆-C₁₀-aryl, optionally substituted by one or more, preferably one group selected from among, —

C₁-C₄-alkyl, —

OH, halogen, —

C(halogen)₃, —

O—

C₁-C₄-alkyl, —

NH₂, —

NH—

C₁-C₄-alkyl, —

N(C₁-C₄-alkyl)₂, and a nitrogen containing heteroaromatic ring, wherein said nitrogen containing heteroaromatic ring may optionally be substituted by one or more, preferably one group selected from among —

C₁-C₄-alkyl, —

OH, halogen, —

C(halogen)₃, and —

O—

C₁-C₄-alkyl, and wherein said nitrogen containing heteroaromatic ring my optionally be linked to the —

C₆-C₁₀-aryl group via a bridging group selected from among —

O—

, —

S—

, and —

NH—

, or

R² is a group selected from among

wherein

X is either N or —

CR³—

;

Y is either —

NR⁵—

, —

O—

, —

S—

, —

SO₂—

, —

CH₂—

or —

CO—

;

A is absent or a ring system selected from among

B is absent or a ring system selected from among

 

rein the arrows indicate the positions where the ring is annellated to the five membered nitrogen heterocycle, and wherein

R³ is selected from among hydrogen, —

C₁-C₄-alkyl, —

CH₂—

NH₂, —

CH₂—

NH—

C₁-C₄-alkyl, —

CH₂—

N(C₁-C₄-alkyl)₂, —

NH₂, —

NH—

C₁-C₄-alkyl, and —

N(C₁-C₄-alkyl)₂;

R⁴ is selected from among hydrogen, —

C₁-C₄-alkyl, —

OH, halogen, —

C(halogen)₃ and —

O—

C₁-C₄-alkyl,

R⁵ is selected from among hydrogen, —

C₁-C₄-alkyl, —

C₆-C₁₀-aryl, and —

C₁-C₄-alkylen-C₆-C₁₀-aryl;

a pharmaceutically acceptable acid addition salt thereof, a hydrate or solvate thereof, or in the form of the individual optical isomer, mixture of the individual enantiomers or a racemate thereof.

2. ) The method for the treatment of female sexual disorders according to claim 1, wherein the disorder is selected from the group consisting of Hypoactive Sexual Desire Disorder, loss of sexual desire, lack of sexual desire, decreased sexual desire, inhibited sexual desire, loss of libido, libido disturbance, and frigidity.

3. ) The method for the treatment of female sexual disorders according to claim 1, wherein the disorder is selected from premenstrual disorders.

4. ) The method for the treatment of female sexual disorders according to claim 1, wherein the disorder is sexual aversion disorder.

5. ) The method for the treatment of female sexual disorders according to claim 1, wherein the disorder is sexual arousal disorder.

6. ) The method for the treatment of female sexual disorders according to claim 1, wherein the disorder is orgasmic disorder.

7. ) The method for the treatment of female sexual disorders according to claim 1, wherein the disorder is a sexual pain disorder.

8. ) The method for the treatment of female sexual disorders according to claim 1, comprising administration of a therapeutically effective amount of a compound of formula 1, wherein

R¹ is a group selected from among fluorine, chlorine, —

O-methyl, and —

CF₃, preferably chlorine and —

CF₃;

L is a linker, selected from the bridging groups —

C₁-C₄-alkylene, —

C₁-C₃-alkylene-O—

, —

C₁-C₃-alkylene-O—

CO—

, —

C₁-C₃-alkylene-NH—

, —

C₁-C₃-alkylene-NH—

CO—

, and —

C₂-C₄-alkenylene, which may optionally be substituted by one or more, preferably one group selected from among methyl, ethyl, propyl, —

OH, chlorine, fluorine, =0 and —

CF₃;

R² is —

NH₂, —

NHC₁-C₄-alkyl, —

N(C₁-C₄-alkyl)₂, or a group selected from among —

C₁-C₄-alkyl and —

C₃-C₆-cycloalkyl which may optionally be substituted by one or more, preferably one group selected from among —

OH, fluorine, chlorine, ═

O, —

CF₃, —

O-phenyl, —

O-naphthyl, —

NH₂, —

NHmethyl, —

N(methyl)₂, —

C₂-C₄-alkenyl and —

C₂-C₄-alkynyl, or

R² is a phenyl or naphthyl group, optionally substituted by one or more, preferably one group selected from among, methyl, ethyl, —

OH, fluorine, chlorine, —

CF₃, —

O-methyl, —

O-ethyl, —

NH₂,

—

NH-methyl, —

N(methyl)₂, and a nitrogen containing heteroaromatic ring selected from among pyridine, pyrimidine, indol, pyrrole, imidazole, pyrazole, triazole, chinoline and isochinoline, wherein said nitrogen containing heteroaromatic ring may optionally be substituted by one or more, preferably one group selected from among methyl, ethyl, —

OH, fluorine, chlorine, —

CF₃, —

O-methyl and —

O-ethyl, and wherein said nitrogen containing heteroaromatic ring my optionally be linked to the phenyl or naphthyl group via a bridging group selected from among —

O— and

—

NH—

, or

R² is a group selected from among

wherein

X is either N or —

CR³—

;

Y is either —

NR⁵—

, —

O—

, or —

CO—

;

A is absent or a ring system selected from among

B is absent or a ring system selected from among

 

wherein the arrows indicate the positions where the ring is annellated to the five membered nitrogen heterocycle, and wherein

R³ is selected from among hydrogen, methyl, ethyl, propyl, —

CH₂—

N(methyl)₂, and —

N(methyl)₂;

R⁴ is selected from among hydrogen, methyl, ethyl, propyl, —

OH, chlorine, fluorine and —

CF₃,

R⁵ is selected from among hydrogen, methyl, ethyl, propyl, phenyl, —

CH₂—

CH₂-phenyl and Benzyl;

a pharmaceutically acceptable acid addition salt thereof, a hydrate and/or solvate thereof, or in the form of the individual optical isomer, a mixture of the individual enantiomers or a racemate thereof.

9. ) The method for the treatment of female sexual disorders according to claim 1, comprising administration of a therapeutically effective amount of a compound of formula 1, wherein

R¹ is a group selected from among fluorine, chlorine, —

O-methyl, and —

CF₃, preferably chlorine and —

CF₃;

L is a linker, selected from the bridging groups —

C₁-C₄-alkylene, —

C₁-C₃-alkylene-O—

, —

C₁-C₃-alkylene-O—

CO—

, —

C₁-C₃-alkylene-NH—

, —

C₁-C₃-alkylene-NH—

CO—

, and —

C₂-C₄-alkenylene, which may optionally be substituted by one or more, preferably one group selected from among methyl, ethyl, propyl, —

OH, chlorine, fluorine, =0 and —

CF₃;

R² is —

NH₂, —

NHC, —

C₄-alkyl, —

N(C₁-C₄-alkyl)₂, or a group selected from among —

C₁-C₄-alkyl and —

C₃-C₆-cycloalkyl which may optionally be substituted by one or more, preferably one group selected from among —

OH, fluorine, chlorine, ═

O, —

CF₃, —

O-phenyl, —

O-naphthyl, —

NH₂, —

NHmethyl, —

N(methyl)₂, —

C₂-C₄-alkenyl and —

C₂-C₄-alkynyl, or

R² is a phenyl or naphthyl group, optionally substituted by one or more, preferably one group selected from among, methyl, ethyl, —

OH, fluorine, chlorine, —

CF₃, —

O-methyl, —

O-ethyl, —

NH₂,

—

NH-methyl, —

N(methyl)₂, and a nitrogen containing heteroaromatic ring selected from among pyridine, pyrimidine, indol, pyrrole, imidazole, pyrazole, triazole, chinoline and isochinoline, wherein said nitrogen containing heteroaromatic ring may optionally be substituted by one or more, preferably one group selected from among methyl, ethyl, —

OH, fluorine, chlorine, —

CF₃, —

O-methyl and —

O-ethyl, and wherein said nitrogen containing heteroaromatic ring my optionally be linked to the phenyl or naphthyl group via a bridging group selected from among —

O— and

—

NH—

, or

R² is a group selected from among.

wherein

X is either N or —

CR³—

;

R³ is selected from among hydrogen, methyl, ethyl, propyl, —

CH₂—

N (methyl)₂, and —

N(methyl)₂;

A is a ring system selected from among

wherein the arrows indicate the positions where the ring is annellated to the five membered nitrogen heterocycle, and wherein

R⁴ is selected from among hydrogen, methyl, ethyl, propyl, —

OH, chlorine, fluorine and —

CF₃,

a pharmaceutically acceptable acid addition salt thereof, a hydrate and/or solvate thereof, or in the form of the individual optical isomer, a mixture of the individual enantiomers or a racemate thereof.

10. ) The method for the treatment of female sexual disorders according to claim 1, comprising administration of a therapeutically effective amount of a compound of formula 1, wherein

R¹ is a group selected from among chlorine and —

CF₃, preferably —

CF₃;

L is a linker, selected from —

CH₂—

CH₂—

, —

CH₂—

CH₂—

CH₂—

, —

CH₂—

CH₂—

CH₂—

CH₂—

, —

O—

CH₂—

CH₂—

, —

O—

CH₂—

CH₂—

CH₂—

, —

O—

CH₂—

CH₂—

CH₂—

CH₂—

, —

CO—

O—

CH₂—

CH₂—

, —

CO—

O—

CH₂—

CH₂—

CH₂—

, —

CO—

O—

CH₂—

CH₂—

CH₂—

CH₂—

, —

NH—

CH₂—

CH₂—

, —

N H—

CH₂—

CH₂—

CH₂—

, —

N H—

CH₂—

CH₂—

CH₂—

CH₂—

, —

CO—

N H—

CH₂—

CH₂—

, —

CO—

NH—

CH₂—

CH₂—

CH₂— and

—

CO—

NH—

CH₂—

CH₂—

CH₂—

CH₂—

, which may optionally be substituted by one or more, preferably one group selected from among methyl, —

OH, fluorine, and —

CF₃;

R² is —

NH₂, —

NHC₁-C₄-alkyl, —

N(C₁-C₄-alkyl)₂, or a group selected from among methyl and ethyl which may optionally be substituted by one or more, preferably one group selected from among —

OH, fluorine, chlorine, ═

O, —

CF₃, —

O-phenyl, and —

NH₂, or

R² is a group selected from among cyclopentyl and cyclohexyl, which may optionally be substituted by one or more, preferably one group selected from among —

OH, fluorine, —

CF₃, and —

C≡

C—

, or

R² is a phenyl group, optionally substituted by one or more, preferably one group selected from among, methyl, —

OH, fluorine, —

CF₃, —

NH₂, and a nitrogen containing heteroaromatic ring selected from among pyridine, pyrimidine, indol, pyrrole, imidazole, pyrazole, triazole, chinoline and isochinoline, wherein said nitrogen containing heteroaromatic ring may optionally be substituted by one or more, preferably one group selected from among methyl, —

OH, fluorine, and —

CF₃, and wherein said nitrogen containing heteroaromatic ring my optionally be linked to the phenyl group via a bridging group selected from among —

O— and

—

NH—

, or

R² is a group selected from among

wherein

X is either N or —

CH—

;

Y is —

O—

or —

CO—

;

A is absent or a ring system selected from among

B is absent or a ring system selected from among

wherein the arrows indicate the positions where the ring is annellated to the five membered nitrogen heterocycle, and wherein

R⁴ is selected from among hydrogen, methyl, —

OH, fluorine and —

CF₃,

a pharmaceutically acceptable acid addition salt thereof, a hydrate and/or solvate or in the form of the individual optical isomer, a mixture of the individual enantiomers or a racemate thereof.

11. ) The method for the treatment of female sexual disorders according to claim 1, comprising administration of a therapeutically effective amount of a compound of formula 1, wherein

R¹ is a group selected from among chlorine and —

CF₃, preferably —

CF₃;

L is a linker, selected from —

CH₂—

CH₂—

, —

CH₂—

CH₂—

CH₂—

, —

CH₂—

CH₂—

CH₂—

CH₂—

, —

O—

CH₂—

CH₂—

, —

O—

CH₂—

CH₂—

CH₂—

, —

O—

CH₂—

CH₂—

CH₂—

CH₂—

, —

CO—

O—

CH₂—

CH₂—

, —

CO—

O—

CH₂—

CH₂—

CH₂—

, —

CO—

O—

CH₂—

CH₂—

CH₂—

CH₂—

, —

NH—

CH₂—

CH₂—

, —

NH—

CH₂—

CH₂—

CH₂—

, —

NH—

CH₂—

CH₂—

CH₂—

CH₂—

, —

CO—

NH—

CH₂—

CH₂—

, —

CO—

NH—

CH₂—

CH₂—

CH₂— and

—

CO—

NH—

CH₂—

CH₂—

CH₂—

CH₂—

, which may optionally be substituted by one or more, preferably one group selected from among methyl, —

OH, fluorine, and —

CF₃;

R² is —

NH₂, —

NHC₁-C₄-alkyl, —

N(C₁-C₄-alkyl)₂, or a group selected from among methyl and ethyl which may optionally be substituted by one or more, preferably one group selected from among —

OH, fluorine, chlorine, ═

O, —

CF₃, —

O-phenyl, and —

NH₂, or

R² is a group selected from among cyclopentyl and cyclohexyl, which may optionally be substituted by one or more, preferably one group selected from among —

OH, fluorine, —

CF₃, and —

C≡

C—

, or

R² is a phenyl group, optionally substituted by one or more, preferably one group selected from among, methyl, —

OH, fluorine, —

CF₃, —

NH₂, and a nitrogen containing heteroaromatic ring selected from among pyridine, pyrimidine, indol, pyrrole, imidazole, pyrazole, triazole, chinoline and isochinoline, wherein said nitrogen containing heteroaromatic ring may optionally be substituted by one or more, preferably one group selected from among methyl, —

OH, fluorine, and —

CF₃, and wherein said nitrogen containing heteroaromatic ring my optionally be linked to the phenyl group via a bridging group selected from among —

O— and

—

NH—

, or

R² is a group selected from among

wherein

X is either N or —

CH—

;

R³ is selected from among hydrogen, isopropyl and —

CH₂—

N(methyl)₂;

A is a ring system selected from among

wherein the arrows indicate the positions where the ring is annellated to the five membered nitrogen heterocycle, and wherein

R⁴ is selected from among hydrogen, methyl, —

OH, fluorine and —

CF₃,

a pharmaceutically acceptable acid addition salt thereof, a the hydrate and/or solvate thereof, or in the form of the individual optical isomer, a mixture of the individual enantiomers or a racemate thereof.

12. ) A pharmaceutical composition for the treatment of female sexual disorders comprising a compound of formula 1 according to claim 1.

13. ) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula 1 according to claim 1 in combination with a therapeutically effective amount of one or more, preferably one active ingredient, preferably an active ingredient selected from the group consisting of melanocortin agonists, prostaglandin E1 agonists, elevators of cyclic guanosine 3′

,5′

-monophosphate (cGMP) (preferably PDE V inhibitors), 5-HT-1A agonists, dopamine agonists, dopamine D4 antagonist and 5-HT-2A/C antagonists.